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Abstract
Background: Claudin-6 is a candidate tumor suppressor gene in breast cancer, and has been shown to be
regulated by DNA methylation and histone modification in breast cancer lines. However, the expression of claudin-
6 in breast invasive ductal carcinomas and correlation with clinical behavior or expression of other markers is
unclear. We considered that the expression pattern of claudin-6 might be related to the expression of DNA
methylation associated proteins (methyl-CpG binding protein 2 (MeCP2) and DNA methyltransferase 1 (DNMT1))
and histone modification associated proteins (histone deacetylase 1 (HDAC1), acetyl-histone H3 (H3Ac) and acetyl-
histone H4 (H4Ac)).
Methods: We have investigated the expression of claudin-6, MeCP2, HDAC1, H3Ac and H4Ac in 100 breast invasive
ductal carcinoma tissues and 22 mammary gland fibroadenoma tissues using immunohistochemistry.
Results: Claudin-6 protein expression was reduced in breast invasive ductal carcinomas (P < 0.001). In contrast,
expression of MeCP2 (P < 0.001), DNMT1 (P = 0.001), HDAC1 (P < 0.001) and H3Ac (P = 0.004) expressions was
increased. Claudin-6 expression was inversely correlated with lymph node metastasis (P = 0.021). Increased
expression of HDAC1 was correlated with histological grade (P < 0.001), age (P = 0.004), clinical stage (P = 0.007)
and lymph node metastasis (P = 0.001). H3Ac expression was associated with tumor size (P = 0.044) and clinical
stage of cancers (P = 0.034). MeCP2, DNMT1 and H4Ac expression levels did not correlate with any of the tested
clinicopathological parameters (P > 0.05). We identified a positive correlation between MeCP2 protein expression
and H3Ac and H4Ac protein expression.
Conclusions: Our results show that claudin-6 protein is significantly down-regulated in breast invasive ductal
carcinomas and is an important correlate with lymphatic metastasis, but claudin-6 down-regulation was not
correlated with upregulation of the methylation associated proteins (MeCP2, DNMT1) or histone modification
associated proteins (HDAC1, H3Ac, H4Ac). Interestingly, the expression of MeCP2 was positively correlated with the
expression of H3Ac and H3Ac protein expression was positively correlated with the expression of H4Ac in breast
invasive ductal carcinoma
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Background
Breast cancer is the most common cancer in women
worldwide and the leading cause of death among
women with cancer [1]. It has been estimated that 230,
480 women would be diagnosed with and 39, 520
women would die of cancer of the breast in 2011.
http://seer.cancer.gov/statfacts/html/breast.html.
It is widely accepted that the loss of cell-to-cell adhe-
sion in tumor-derived epithelium is necessary for the
invasion of surrounding stromal elements and subse-
quent tumor metastasis [2]. The cell-to-cell adhesion of
epithelial cells is primarily mediated through two types
of junctions: adherens junctions and tight junctions.
Tight junctions consist of three parts, depending on
their distribution within the junction: transmembrane
proteins (which include occludins, the claudin family
and junctional adhesion molecules), cytoplasmic plaques
(the zonula occludens family), and associated/regulatory
proteins (Rho-subfamily proteins) [3].
The claudin family includes at least 27 members [4,5].
Claudin-6 contains four transmembrane domains, simi-
lar to other members of the claudin family [6]. Recent
studies have demonstrated that epigenetic mechanisms
are essential for claudin regulation [7-9]. The most stu-
died epigenetic regulators are DNA methylation and his-
tone modification [10]. MeCP2 is a methyl-CpG binding
protein that represses gene transcription. DNA methyl-
transferases are crucial enzymes for hypermethylation of
tumor suppressor genes [11]. DNA methyltransferase 1
(DNMT1) is the best known and studied member of the
DNMT family [12]. Moreover, DNA methylation occurs
in a complex chromatin network and is influenced by
modifications in histone structure [13,14]. Histone dea-
cetylase 1 (HDAC1), a zinc-dependent deacetylase, is a
member of class I histone deacetylases, it is deregulated
in many cancers and plays a crucial role in cell cycle
progression and proliferation [15]. However, the expres-
sion levels of histone deacetylase 1 in breast invasive
ductal carcinoma do not appear to have been studied.
We hypothesized that alterations in the expression
levels of several epigenetic regulators, such as MeCP2,
DNMT1, HDAC1, H3Ac and H4Ac, are responsible for
the loss of claudin-6 in breast invasive ductal carcino-
mas. Here, we have analysed 100 breast invasive ductal
carcinomas and 22 mammary gland fibroadenomas by
immunohistochemistry. Our results demonstrate
decreased claudin-6 expression in 75% of our cases of
invasive breast carcinomas. Claudin-6 expression was
found to be independent of the tumor subtype but was
inversely correlated with lymph node metastasis.
Methods
Specimen collection
The breast specimens consisted of 100 invasive ductal
carcinomas (IDC) and 22 fibroadenomas (FA) obtained
during the period 2006 to 2010 from patients being
treated at the Jilin Oil Field General Hospital in Son-
gyuan, China. In 100 IDC cases, there were 15 tumor
free mammary gland tissues which were employed as
normal controls. The study was approved by the Ethics
Committee of Jilin University. All specimens had been
fixed in 4% buffered formalin and embedded in paraffin.
The case diagnoses were based on the World Health
Organization (WHO) classification of breast cancer [16].
The presence or absence of cancer metastasis was deter-
mined at the time of the operation. Material collection
and the clinical features of the patients are described in
Tables 1 and 2.
Immunohistochemistry
Four-micrometer-thick tissue sections were cut from the
paraffin-embedded blocks. Deparaffinization was per-
formed using a solution containing xylene, and the sec-
tions were rehydrated with graded ethanol. The slides
were placed in target retrieval solution (citrate buffer,
pH 6.0) and boiled for 5 min in a microwave. After the
samples were cooled for 30 min, endogenous peroxidase
activity was inhibited by treatment with 3% H2O2 for 30
min. The sections were washed with PBS three times.
After a 30-min protein block with normal goat serum or
normal rabbit serum, the samples were incubated with
the following antibodies overnight at 4°C: anti-claudin-6
(1:500; Santa Cruz Biotechnologies, Santa Cruz, CA,
USA), anti-MeCP2 (1:400; 3456, Cell Signalling Tech-
nology, Inc., Boston, MA, USA), anti-DNMT1 (1:500;
GTX116011, Gene Tex, Inc., USA), anti-HDAC1 (E47)
( 1 : 4 0 0 ;B S 5 5 7 6 ,B i o w o r l dT e c h n o l o g y ,I n c . ,U S A ) ,a n t i -
acetyl-histone H3 (K9) (1:400; BS8009, Bioworld Tech-
nology, Inc., USA), anti-acetyl-histone H4 (K12) (1:400;
BS8010, Bioworld Technology, Inc., USA). Immunos-
taining was performed using the streptavidin-biotin-per-
oxidase complex. The biotin-conjugated secondary
antibody was incubated for 30 min at room tempera-
ture. In addition, the colour reagent diaminobenzidine
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Page 2 of 12Table 1 Expression of CLDN6, MeCP2 and DNMT1 and clinicopathological characteristics in breast invasive ductal
carcinoma patients
Variables Number of cases
(%)
Claudin-6 MeCP2 DNMT1
Positive
(%)
Negative
(%)
P Positive
(%)
Negative
(%)
P Positive
(%)
Negative
(%)
P
Breast invasive ductal
carcinoma
100(100%) 25(25%) 75(75%) <
0.001
88(88%) 12(12%) <
0.001
69(69%) 31(31%) 0.001
Control 22(100%) 20 (91%) 2 (9%) 6 (27%) 16(73%) 7(32%) 15(68%)
Age (year)
≤ 40 20(20%) 5(25%) 15(75%) 1.000 16(80%) 4(20%) 0.251* 15(75%) 5(25%) 0.060
> 40 80(80%) 20(33%) 60(67%) 72(90%) 8(10%) 73(91%) 7(9%)
Tumour size(cm)
≤ 5 91(91%) 24(26%) 67(63%) 0.444* 80(88%) 11(12%) 1.000* 65(71%) 26(29%) 0.131
> 5 9 (9%) 1(11%) 8(89%) 8(89%) 1(11%) 4(44%) 5(56%)
Differentiation
well 25(25%) 9(36%) 16(64%) 0.142 21(84%) 4(16%) 0.488* 17(68%) 8(32%) 0.902
poor 75(75%) 16(21%) 59(79%) 67(89%) 8(11%) 50(67%) 25(33%)
Clinical stage
I 20(20%) 5(21%) 19(79%) 0.760 18(90%) 2(10%) 0.074* 10(50%) 10(50%) 0.113
II 46(46%) 10(22%) 36(78%) 37(80%) 9(20%) 35(76%) 11(24%)
III-IV 34(34%) 10(29%) 24(71%) 33(97%) 1(3%) 23(68%) 11(32%)
Lymph node metastasis
Positive 48(48%) 7(15%) 41(85%) 0.021 43(90%) 5(10%) 0.640 34(71%) 14(29%) 0.972
Negative 52(52%) 18(35%) 34(65%) 45(87%) 7(13%) 37(71%) 15(29%)
MeCP2 Methyl-CpG-binding proteins, DNMT1 DNA methyl transferase 1. * Fisher’s exact text
Table 2 Expression of HDAC1, H3Ac and H4Ac and clinicopathological characteristics in breast invasive ductal
carcinoma patients
Variables Number of cases
(%)
HDAC1 H3Ac H4Ac
Positive
(%)
Negative
(%)
P Positive
(%)
Negative
(%)
P Positive
(%)
Negative
(%)
P
Breast invasive ductal
carcinoma
100(100%) 67(67%) 33(33%) 90(90%) 10(10%) 79(79%) 21(21%) 0.243*
Control 22(100%) 3 (14%) 19(86%) <
0.001
14(64%) 8 (36%) 0.004* 20(91%) 2 (9%)
Age (year)
≤ 40 20(20%) 8(40%) 12(60%) 0.004 18(90%) 2(10%) 1.000* 17(85%) 3(15%) 0.554*
> 40 80(80%) 59(74%) 21(26%) 72(90%) 8(10%) 62(78%) 18(22%)
Tumour size(cm)
≤ 5 91(91%) 62(68%) 29(22%) 0.472* 84(92%) 7(8%) 0.044* 74(81%) 17(19%) 0.089*
> 5 9 (9%) 5(56%) 4(44%) 6(67%) 3(23%) 5(56%) 4(44%)
Differentiation
well 25(25%) 8(32%) 17(68%) <
0.001
24(96%) 1(4%) 0.444* 20(80%) 5(20%) 0.887
poor 75(75%) 59(79%) 16(21%) 66(88%) 9(12%) 59(79%) 16(21%)
Clinical stage
I 20(20%) 12(60%) 8(40%) 0.007 17(85%) 3(15%) 0.034* 18(90%) 2(10%) 0.227
II 46(46%) 38(83%) 8(17%) 45(98%) 1(2%) 37(80%) 9(20%)
III-IV 34(34%) 17(50%) 17(50%) 28(82%) 6(18%) 24(71%) 10(29%)
Lymph node metastasis
Positive 48(48%) 40(83%) 8(17%) 0.001 43(90%) 5(10%) 1.000* 37(77%) 11(23%) 0.651
Negative 52(52%) 27(52%) 25(48%) 47(90%) 5(10%) 42(81%) 10(19%)
HDAC1 histone deacetylase 1, H3Ac acetyl-Histone H3, H4Ac, acetyl-Histone H4. * Fisher’s exact text
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antibody. The sections were counterstained with Mayer’s
haematoxylin.
Evaluation of cellular phenotypes
The number of positive-staining cells showing brown
staining on the cell membrane and/or cytoplasm (for
claudin-6) and nucleus (for MeCP2, DNMT1, HDAC1,
H3Ac and H4Ac) in 5 randomly-selected 400× micro-
scopic fields was counted and the percentage of positive
cells was calculated.
Claudin-6 expression in more than 10% of tumor cells
was defined as high expression [17]. Immunostaining
results for DNMT1 [18,19] and HDAC1 [20] were inter-
preted as high expression when > 20% of the tumor
cells were stained. MeCP2 expression in more than 15%
of tumor cells was defined as high expression. H3Ac
and H4Ac expression in more than 40% of tumor cells
was defined as high expression.
All immunohistochemical analyses were evaluated
separately by two pathologists (C.S.Q and K.P.Q), and
discordant results were reviewed to reach an agreement.
Statistical analyses
Statistical analysis was performed using SPSS 15.0. The
Student’sTt e s t sa n dt h eM a n n - W h i t n e yU test were
performed. Comparisons between sample groups were
analysed for statistical significance using the Χ
2-test and
Fisher’s exact test. The Spearman’s correlation test was
used to examine the correlation among claudin-6,
MeCP2, DNMT1, HDAC1, H3Ac and H4Ac levels. All
P values quoted are two-sided and P <0 . 0 5w a sc o n s i d -
ered statistically significant.
Results
Population and tumor characteristics
The clinicopathological characteristics of the patients
are summarised in Tables 1 and 2. The mean age of
patients with breast invasive ductal carcinoma was
50.5 years (range: 31-87 years). Negative nodes were
found in 52 cases. A total of 31 cases had between
1 and 3 metastatic nodes, and 17 cases had more than
3 positive nodes.
Protein expression in fibroadenomas and normal breast
tissue
We examined the expression of claudin-6, DNMT1,
MeCP2, HDAC1, H3Ac and H4Ac in normal breast
tissue adjacent to the carcinomas and in FA tumors
(Figures 1, 2 and 3). There was no difference in the
expression of these proteins between normal tissues
adjacent to the tumors and in breast fibroadenomas
(Table 3). Consequently, we chose the fibroadenomas as
a control tissue.
The expression of claudin-6 was reduced in breast
invasive ductal carcinomas and was correlated with
lymph node metastasis
In this study, claudin-6 was evaluated in the cytoplasm
or membranes in 100 cases of breast IDCs and 22 breast
FA samples. Positive expression of claudin-6 protein was
found in 25% (25/100) of breast IDCs and in 91% (20/
22) of breast FA cases (Table 1). The expression rate of
claudin-6 in IDCs [median = 6.0% (P25 =4 . 0 % ,P 75 =
11.8%)] was lower than the rate in FAs [28.6% (20.0%,
47.2%)] (Mann-Whitney U test, P <0 . 0 0 1 )( F i g u r e2 A ,
B). As shown in Table 1 the expression of claudin-6
was not correlated with age (P = 1.000), tumor size
(P = 0.444), clinical stage (P = 0.760) or differentiation
(P = 0.142) and was inversely correlated with lymph
node metastasis of the breast invasive ductal carcinomas
(P = 0.021).
The expression of MeCP2 and DNMT1 was increased in
breast invasive ductal carcinomas
The nuclear staining of MeCP2 and DNMT1 was strong
in IDC cells and weak in FA adenocytes. MeCP2 was
expressed in 88% (88/100) of breast IDC samples. The
expression rate was [67.0% (43.5%, 76.0%)] in IDC sam-
ples. Cells were positive for MeCP2 in 27% (6/22) of
breast FA cases. The expression rate was [15.5% (11.5%,
42.3%)]. We conclude that MeCP2 expression is signifi-
cantly high (Figure 2C, D) in breast IDC samples
(Mann-Whitney U test, P < 0.001). The expression level
of DNMT1 was high in most breast IDCs but was low
in breast FAs (Figure 2E, F). The positive expression of
DNMT1 in the 100 breast cancer samples was 69% (69/
100), which was significantly greater than that in the
breast FA tissues 32% (7/22), (P =0 . 0 0 1 ) .T h ea v e r a g e
expression rate of DNMT1 in breast IDCs (25.5% ±
10.3%) was higher than the rate in breast FAs (7.1% ±
5.1%; t = 6.299; P < 0.001). As shown in Table 1, the
expression of MeCP2, DNMT1 did not show any rela-
tionship to the clinicopathological characteristics of
breast IDCs.
MeCP2 expression did not correlate with age (P =
0.251), tumor size (P = 1.000), clinical stage (P = 0.074),
differentiation (P = 0.488) or lymph node metastasis (P
= 0.640). The expression of DNMT1 was not correlated
with age (P = 0.060), tumor size (P = 0.131), clinical
stage (P = 0.113), differentiation (P = 0.902) or lymph
node metastasis (P = 0.972).
The expression of HDAC1 was positively correlated with
the poor differentiation and lymph node metastasis of
breast invasive ductal carcinomas
In the present study, the expression of HDAC1 was
found in 67% (67/100) of breast IDCs, the expression
rate was [26.0% (13.3%, 39.0%)]. The expression of
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expression rate was [11.0% (7.8%, 21.5%)] (Figure 3A,
B). The average expression rate of HDAC1 in breast
IDCs was significantly higher than that in breast FAs
(Mann-Whitney U test, P = 0.002). As shown in Table 2
the expression of HDAC1 was positively correlated with
the poor differentiation (P < 0.001), older age (P =
0.004) clinical stage (P = 0.007) and lymph node metas-
tasis (P = 0.001), but was not related to the tumor size
(P = 0.472) in the breast cancer tissues.
A B
C D
E F
B
Figure 1 Protein expression in normal breast tissue by immunohistochemistry. (A), claudin-6 was expressed; (B), MeCP2; (C), DNMT1; (D),
HDAC1 were expressed at low levels; (E), H3Ac was highly expressed; (F), the strong expression of H4Ac (400×).
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E F
Figure 2 Representative photomicrographs. Immunohistochemical expressions for claudin-6, methy-CpG binding protein 2 (MeCP2) and DNA
methyltransferase 1 (DNMT1) in breast invasive ductal carcinomas (IDC) and fibroadenomas (FA) (×400). (A) claudin-6 was expressed in breast
adenoma cells. Note: the staining on membrane (dotted arrow); the staining in cytoplasm (solid arrow). (B) claudin-6 was weakly expressed in
IDC cells. (C) MeCP2 immunoreactivity was moderate in the FA tissues (arrow). (D), (F) MeCP2 and DNMT1 were strongly expressed in breast IDC
cells, especially at the nuclear (arrow). (E) DNMT1 immunoreactivity was not detected in the breast FA tissues.
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Figure 3 Representative photomicrographs. Immunohistochemical expressions for histone deacetylase 1 (HDAC1), acetyl-histone H3 (H3Ac)
and acetyl-histone H4 (H4Ac) in breast invasive ductal carcinomas (IDC) and fibroadenomas (FA) (×400). (A), (C), (E) breast fibroadenomas; (B),
(D), (F) breast invasive ductal carcinoma. Immunostained for HDAC1 (A, B), H3Ac (C, D) or H4Ac (E, F). nuclear staining (arrow).
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size and clinical stage in breast invasive ductal
carcinomas
The expression of H3AC was found in 90% (90/100) of
breast IDCs, whereas the expression was found in 64%
(14/22) of breast FAs. The difference was significant (P
= 0.004) (Figure 3C, D). The average expression rate of
H3Ac in breast IDCs was (63.1% ± 20.0%), which was
significantly higher than that in breast FAs (44.6% ±
20.2%; t = 3.927, P < 0.001). The expression of H3AC
was not correlated with age (P = 1.000), differentiation
(P = 0.444) or lymph node metastasis (P = 1.000). The
expression of H3AC was higher in small tumors (size ≤
5 cm) than in large tumors (size > 5 cm) (P = 0.044)
and was lower in clinical stages I and III-IV than that in
clinical stage II (P = 0.034). The expression of H4AC
was slightly elevated in FA samples compared to IDC
samples. However, this difference was not statistically
significant (P =0 . 2 4 ,F i s h e r ’s exact text) (Figure 3E, F).
H4AC expression was not correlated with any clinico-
pathological parameter (Table 2).
MeCP2, H3Ac and H4Ac may be concurrently expressed
in breast invasive ductal carcinomas
We investigated the correlation among claudin-6,
MeCP2, DNMT1, HDAC1, H3AC and H4AC in 100
breast invasive ductal carcinomas using Spearman’sc o r -
relation test. Although we did not find a correlation
between claudin-6 and MeCP2, DNMT1, HDAC1,
H3AC and H4AC, we found that the expression of
MeCP2 was positively correlated with the expression of
H3Ac (correlation coefficient = 0.206; P = 0.040). More-
over, the expression of H3Ac was significantly positively
correlated with the nuclear expression of H4Ac (correla-
tion coefficient = 0.292; P = 0.001). The detailed results
of the analysis are described in Table 4.
We analysed the association between the loss of clau-
din-6 and the protein expression of the potential
transcriptional repressors MeCP2, HDAC1, H3AC and
H4AC. These results suggest that histone modifications
might account for claudin-6 inhibition in breast IDC.
No correlations were detected between the loss of clau-
din-6 and the upregulation of MeCP2 (P = 0.746) and
H3AC (P = 0.917) in IDC samples.
Discussion
In a previous study, we showed that the protein and
gene expression of claudin-6 was low or undetectable in
human and rat mammary cancer cell lines [21], and the
cell growth, migration and invasion were inhibited by
overexpression of claudin-6 in breast cancer MCF-7
cells. These results suggested that claudin-6 is a tumor
repressor that inhibits malignant progression of breast
cancer [22]. Claudin-6 expression is inactivated by aber-
rant CpG island DNA hypermethylation in its promoter
region in the breast cancer cell MCF-7 [23], suggesting
that DNA methylation may have an important role in
regulation of claudin-6 expression in breast cancer. The
most studied epigenetic regulators are DNA methylation
and histone modification [10]. DNA methylation can
cause gene silencing by interfering with the interactions
between transcriptional activators and target-binding
sites on genomic DNA, condensing the chromatin to
alter DNA accessibility, and recruiting methyl-CpG
binding proteins, which mediate downstream biological
effects [24]. However, whether or not methylation asso-
ciated proteins and histone modification proteins act to
repress claudin-6 expression and how they influence the
clinicopathological characteristics of IDC tumors is not
yet understood. Consequently, our main goal in this
study was to analyze the importance of MeCP2,
DNMT1, HDAC1, H3Ac and H4Ac in the down-regula-
tion of claudin-6 in breast IDC.
We wanted to find the normal mammary gland tissue
as a normal control, but it is rarely available for research
in China. In this study, 15 (15%) of breast cancer cases
Table 3 Expression of CLDN6, MeCP2, DNMT1, HDAC1, H3Ac and H4Ac in breast fibroadenoma tissues and normal
adjacent tissues
Variables Fibroadenoma tissues Normal adjacent tissues P
Expression Claudin-6 (%)
Median (P25, P75)
28 (21, 47) 30 (25, 47) 0.953
a
Expression MeCP2 (%)
Median (P25, P75)
15 (10, 42) 14 (13, 43) 0.813
a
Expression DNMT1 (%)
Median (P25, P75)
6 (3, 14) 6 (4, 16) 0.442
a
Expression HDAC1 (%)
Median (P25, P75)
10 (7, 21) 10 (5, 21) 0.575
a
Expression H3Ac (%)
Mean ± SD
44.2 ± 19.8 45.6 ± 22.4 0.843
b
Expression H4Ac (%)
Mean ± SD
63.3 ± 18.2 61.8 ± 14.7 0.791
b
a Mann-Whitney U test;
b t-student’s test
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tumor samples. Since we regarded this as too small an
amount to be used as a control, we then chose tissue
from fibroadenomas for this purpose. Hua et al. studied
that the expression of fibroblast activation protein-alpha
(FAP-a) and Calponin was a novel marker for patholo-
gically diagnosing whether DCIS had microinvasion, and
FAP-a promoted the formation of microemboli, which
facilitated the metastasis of breast cancer [25]. We also
compared the expression of proteins we studied in tis-
sue adjacent to tumors and in fibroadenomas. There
was no difference in the expression of proteins between
normal tissues adjacent to the 15 tumors, and breast
fibroadenomas (P > 0.05; Table 3). Consequently chose
the fibroadenomas as a control tissue.
In this study, we have shown that the expression of
claudin-6 was observed in both membrane and cyto-
plasm/membrane in the FA and IDC of the breast, simi-
lar to previous studies on the claudin-6 in atypical
teratoid/rhabdoid tumors [26], claudin-1, and claudin-7
in colonic and renal carcinomas, respectively [27,28].
This observation suggests that in breast IDCs and FAs,
claudin-6 has an abnormal cellular localization, and was
not restricted to cell-cell boundaries. Subsequent evalua-
tion by immuno- histochemistry of 25 (25%) IDC sam-
ples and 20 (91%) FA samples showing positive
immunoreactivity for claudin-6, showed that the expres-
sion of claudin-6 was significantly reduced in breast
IDC tissues (P < 0.001). This result indicates that the
reduced expression of claudin-6 may be an important
molecular event in the development of breast cancers.
Next, we investigated the correlation between claudin-6
expression and the clinicopathological characteristics of
breast IDCs. We found that the expression of claudin-6
was negatively correlated with lymphatic metastasis of
breast IDCs. This observation suggested low claudin-6
expression might facilitate lymph node invasion by
tumor cells, and distant metastasis. On the one hand,
the down-regulation of claudin-6 might result in abnor-
mal proliferation, poor differentiation and decrease
apoptosis, and played a role in mammary epithelial cell
malignant transformation in the breast cancers; On the
other hand, the down-regulation of claudin-6 may also
lead to dysfunction of tight junctions, resulting in loss
of cell-cell adhesion and polarity, causing tumor cells
invasion and metastasis.
We have previously investigated the possibility that
the expression of claudin-6 was negatively correlated
with the hypermethylation promoter of claudin-6 in
breast cancer tissues (data unpublished), suggesting that
the down-regulation of claudin-6 is associated with its
DNA methylation. DNA methylation is mediated by
DNA methyltransferases (DNMTs) that catalyze the
transfer of the methyl group from S-adenosyl L-methio-
nine (SAM) to the cytosine in CpG dinucleotide [29].
Maintenance of methylation patterns is mediated by
DNMT1. Altered levels of DNMT1 expression have fre-
quently been associated with several types of tumors.
DNMT1 expression was upregulated in pancreatic can-
cer cells, possibly associated with the progression of dis-
ease symptoms in pancreatic carcinoma [18]. In the
present study, DNMT1 was more highly expressed in
breast IDCs than nonmalignant tissues, but positive
expression of DNMT1 was not associated with any clini-
cal parameters. The Spearman’s correlation test showed
that claudin-6 expression was not correlated with the
DNMT1 expression, but there were 56 cases of IDC in
which the expression of claudin-6 and DNMT1 showed
a reverse trend. The results show that the increased
expression of DNMT1 plays an important role in the
Table 4 Correlation between the expression of claudin-6, MeCP2, DNMT1, HDAC1, H3AC and H4AC
Expression of
MeCP2
Expression of
DNMT1
Expression of
HDAC1
Expression of
H3Ac
Expression of
H4Ac
Expression of
claudin-6
Correlation
coefficient
-0.033 -0.147 -0.091 -0.011 -0.072
P value 0.746 0.145 0.369 0.917 0.478
Expression of
MeCP2
Correlation
coefficient
0.060 0.019 0.206 0.162
P value 0.552 0.855 0.040 0.107
Expression of
HDAC1
Correlation
coefficient
0.023 0.126 -0.025
P value 0.821 0.210 0.804
Expression of
DNMT1
Correlation
coefficient
0.072 0.110
P value 0.473 0.278
Expression of H3Ac Correlation
coefficient
0.292
P value 0.001
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Page 9 of 12progression of breast IDC and that claudin-6 is partly
inhibited by DNMT1.
MeCP2, the most studied member of the methyl-CpG
binding domain proteins (MBDs), binds methylated
DNA, and also serves as a transcriptional repressor [30].
Therefore, we considered whether claudin-6 expression
might be related to the expression of MeCP2 in breast
IDCs. Our results show that MeCP2 protein expression
was statistically significantly higher in breast IDC speci-
mens than in non-neoplastic lesions, although MeCP2
was not associated with any clinical parameters. The
expression of claudin-6 was not significantly correlated
with the expression of MeCP2, just as Wojdacz’ s
research, the methylation of breast cancer related genes
(BRCA1, APC and RASSF1A) in peripheral blood DNA
did not directly link to somatic methylation of the same
genes in tumor DNA [31]. But there also were 74 cases
of breast IDC in which the expression of claudin-6 and
MeCP2 showed a reverse trend, suggesting that the
increased expression of MeCP2 also played an important
role in the progression of breast IDC. Similarly, MeCP2
mRNA expression levels have be shown to be increased
in breast cancer specimens [32]. In addition to binding
methylated DNA sequences, MeCP2 contains a C-term-
inal transcriptional repression domain which has been
identified as the region involved in the gene repression
activity [33]. MeCP2 binds methylation of the breast
cancer 1 gene (BRCA1) and MAGE-A promoter, and
results in tumor suppression [34,35]. Our group has pre-
viously found that MeCP2 can bind the promoter of
claudin-6 in breast cancer cell line MCF-7 (data unpub-
lished), A number of studies have shown that MeCP2 is
responsible for the initial recruitment of HDAC1, Sin3A
and HDAC2, forming a tumor suppressor complex and
were essential for MeCP2-mediated tumor suppression
[36,37].
Histone deacetylases are modification enzymes that
catalyze the removal of acetyl molecules from lysines to
balance the activities of histone acetyl-transferases [38].
Previous studies have shown that HDAC1 was overex-
pressed in many cancers, including gastric [39], colorec-
tal [40] and pancreatic [41] carcinomas. To investigate
the interactions between claudin-6 and HDAC1, H3Ac
and H4Ac, we evaluated the expression patterns and the
relation among the HDAC1, H3Ac and H4Ac in the
breast IDC. In our series, HDAC1 expression was
increased in IDC specimens relative to breast FA speci-
mens. Interestingly, our data suggested that up-regula-
tion of HDAC1 favored tumor cell metastasis, as
evidenced by the fact that those tumors showing
increased HDAC1 expression correlated with poor dif-
ferentiation, older age, lymph node metastasis. There-
fore, our data indicate that higher expression levels of
HDAC1 are correlated with more aggressive tumors.
This finding was not consistent with the observations of
Krusche et al [42], who showed that HDAC1 expression
predicted a better prognosis. The reasons for these
results is unknown and the clinical significance of
HDAC1 expression at the protein level in breast IDC
also needs to be confirmed in a larger patient cohort.
The Spearmen’s relation test showed the expression of
HDAC1 was not correlated with the expression of clau-
din-6, but there also were 64 cases of breast IDC in
which the expression of claudin-6 and HDAC1 showed
a reverse trend, suggesting that there was a partial role
of increased expression HDAC1 in repressing the
expression of claudin-6. Histone modifications (e.g. acet-
ylation, methylation) are important regulators of tran-
scriptional activities; therefore, we evaluated the total
histone H3 acetylation (H3Ac) and histone H4 acetyla-
tion (H4Ac) by immunohistochemistry. In the present
study, H3Ac expression levels were markedly increased
in IDC specimens compared to breast FA specimens.
H3Ac levels were increased in tumors < 5 cm in size
and cancers of clinical stage I and II. H4Ac protein
expression was high in IDC. However, we found no sta-
tistically significant correlations between H4Ac and clin-
icopathological parameters. We did not find statistically
significant correlation between claudin-6 and H3Ac,
H4Ac. These results therefore suggest that DNA methy-
lation and histone modification play only a partial role
in inhibition of claudin-6 expression. MeCP2, DNMT1,
HDAC1, H3Ac and H4Ac might form a repressor com-
plex, and inhibit the expression of claudin-6. Whether
or not such complex might be responsible for the
down-regulation of claudin-6 observed in our cases
would require further investigation. Interestingly, Spear-
man’s correlation test showed the expression of MeCP2
was positively correlated with the expression of H3Ac
and H3Ac expression positively correlated with the
expression of H4Ac. These results indicate that the
expression of DNA methylation associated gene
(MeCP2) may influence the expression of histone acety-
l a t i o n( H 3 A ca n dH 4 A c )i nb r e a s tI D Ca n dt h a tt h e
expressions of MeCP2, H3Ac and H4Ac play an impor-
tant role in the generation of breast IDC.
We would have liked to include a survival analysis of
the IDCs, but the breast cancer cases were mostly from
the period 2009-2010, only two or three years after sur-
gery. The 5-year survival rate seems to be more mean-
ingful for assessment than nodal metastasis. This
research is being conducted now and we hope to be
able to publish the data in the future.
Conclusions
In summary, our data indicates that claudin-6 is down-
r e g u l a t i o ni nb r e a s tI D Ca n dt h a ti ti sm e d i a t e db y
molecular mechanisms other than aberrant expression
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Page 10 of 12of the methylation associated proteins (MeCP2,
DNMT1) and histone modification associated proteins
(HDAC1, H3Ac, H4Ac). The expression of MeCP2 is
positively correlated with the expression of H3Ac and
H4Ac. Our data suggests that down-regulation of clau-
din-6 is an important factor influencing lymphatic
metastasis; whereas up-regulation of HDAC1 is asso-
ciated with tumor progression and invasiveness in breast
IDC.
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